

# SPECIAL SYMPOSIUM: ctDNA Platforms

## *Understanding Our Options and Utility from Colleagues in Industry*

Thursday, October 17, 8:30-10:00 am CT

*A round robin of our colleagues from industry will share concise overviews of their ctDNA platforms at this Thursday morning event. They will then be available at exhibit tables in the Ballroom Foyer for one-on-one questions and conversations on both Thursday and Friday.*

8:30am – Welcome by Lee Ellis, MD, FASCO

- **Tempus**, Calvin Chao, MD, *Senior Vice President of Medical Affairs*
- **Foundation Medicine**, Mia Levy, MD, PhD, *Chief Medical Officer*
- **Natera**, Minetta C. Liu, MD, *Chief Medical Officer, Oncology*
- **Guardant Health**, Thereasa Rich, MS, CGC, *Clinical Evidence Director Global Scientific Affairs*
- **Haystack Oncology**, Dan Edelstein, *Vice President and General Manager*
- **Caris Life Sciences**, Farah Abdulla, MD, FAAD, *Precision Oncology Alliance Vice Chair and Senior Medical Director*

9:35 - 10:00am – Q&A and Closing

Please visit the meeting exhibits to follow up and learn more.

---

**"TEMPUS** Tempus is focused on building the leading AI-enabled Intelligent Diagnostic platform in the world. We are an integrated partner offering a broad range of DNA and RNA sequencing services. We are improving patient care through comprehensive testing, clinical trial matching, and deep research data that powers scientific discovery. Through our scientific publications and research projects, we are accelerating and transforming personalized patient care. We generate insights at scale to help doctors make better decisions, drug companies make better drugs, and patients live longer and healthier lives.



**FOUNDATION  
MEDICINE®**

**Foundation Medicine is a pioneer in molecular profiling for cancer, working to shape the future of clinical care and research.** We collaborate with a broad range of partners across the cancer community and strive to set the standard for quality, scientific excellence, and regulatory leadership. Our deep understanding of cancer biology helps physicians make informed treatment decisions for their patients and empowers researchers to develop new medicines. Every

day, we are driven to help our partners find answers and take action, enabling more people around the world to benefit from precision cancer care. For more information, please visit [FoundationMedicine.com](https://www.FoundationMedicine.com).



**Signatera is a personalized, tumor-informed, molecular residual disease test for patients previously diagnosed with cancer.** Custom-built for each individual, Signatera uses circulating tumor DNA to detect and quantify cancer left in the body, identify recurrence earlier than standard of care

tools, and help optimize treatment decisions. The test is available for clinical and research use and is covered by Medicare for patients with colorectal cancer, breast cancer, ovarian cancer and muscle-invasive bladder cancer, as well as for immunotherapy monitoring of any solid tumor. Signatera has been clinically validated across multiple cancer types and indications, with published evidence in more than 75 peer-reviewed papers.



**Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer.** Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what

drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit [guardanthealth.com](http://guardanthealth.com) and follow the company on LinkedIn, X (Twitter), and Facebook.



**Haystack MRD™ by Haystack Oncology, a Quest Diagnostics company, is a tumor-informed, next-generation minimal residual disease (MRD) test that detects ultralow levels of circulating tumor**

**DNA (ctDNA) to identify and monitor residual, recurrent, or resistant disease with exquisite sensitivity.** Based on more than 20 years of collaboration to advance technical and clinical development in liquid biopsy technologies by cancer genomics pioneers at Johns Hopkins School of Medicine, Haystack MRD's purpose-built, high-precision science delivers novel insights that can help shape personalized treatment decision-making, accelerate clinical development, and empower clinicians to improve patient lives with more certainty than ever before.



**Caris Life Sciences® is a leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition.** Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced AI and machine learning algorithms, Caris has created the large-scale, multi-modal database and computing capability needed to analyze and unravel the molecular complexity of disease. This convergence of sequencing power, big data and AI technologies provides an unmatched platform to deliver the next

generation of precision medicine tools for early detection, diagnosis, monitoring, therapy selection and drug development. To learn more, please visit [CarisLifeSciences.com](http://CarisLifeSciences.com)